Media stories about Neurocrine Biosciences (NASDAQ:NBIX) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.2055407228976 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 31st. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same period last year, the firm earned ($0.43) EPS.

Several brokerages have issued reports on NBIX. Cowen and Company reissued an “outperform” rating and issued a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Leerink Swann reissued an “outperform” rating and issued a $72.00 price target (up previously from $67.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 10th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $69.31.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences (NBIX) Getting Somewhat Positive News Coverage, Analysis Finds” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2017/11/02/neurocrine-biosciences-nbix-getting-somewhat-positive-news-coverage-analysis-finds.html.

In related news, insider Christopher Flint Obrien sold 6,925 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the transaction, the insider now owns 55,898 shares of the company’s stock, valued at $3,412,013.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the transaction, the insider now directly owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The disclosure for this sale can be found here. In the last ninety days, insiders sold 123,846 shares of company stock valued at $7,004,150. 4.80% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.